Spots Global Cancer Trial Database for A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Study ID: NCT02318394
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors
Detailed Description: This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and preliminary anti-tumor activity in adult subjects with selected advanced solid tumors.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, La Jolla, California, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, Detroit, Michigan, United States
Research Site, Minneapolis, Minnesota, United States
Research Site, Bronx, New York, United States
Research Site, New York, New York, United States
Research Site, Huntersville, North Carolina, United States
Research Site, Portland, Oregon, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Dallas, Texas, United States
Research Site, Houston, Texas, United States
Research Site, Seoul, , Korea, Republic of
Contact Details
Name: Medimmune LLC
Affiliation: MedImmune LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
